CCL17 and Alzheimer disease: Moreover, in another study, a combination of four serum biomarkers, namely TARC/CCL17, PARC/CCL18, IL-22 and soluble IL-2 receptor (sIL-2R), demonstrated a better correlation with disease severity compared to a single biomarker in AD patients [28].